| Quarter | Filling ID |
|---|---|
| Q4 25 | 0002002654-26-000001 |
| Q3 25 | 0002002654-25-000006 |
| Q2 25 | 0002002654-25-000004 |
| Q1 25 | 0002002654-25-000003 |
| Q4 24 | 0002002654-25-000001 |
| Q3 24 | 0002002654-24-000005 |
| Q2 24 | 0002002654-24-000004 |
| Q1 24 | 0002002654-24-000002 |
| Q4 23 | 0002002654-24-000001 |
| Q3 23 | 0002002654-23-000008 |
| Q2 23 | 0002002654-23-000007 |
| Q1 23 | 0002002654-23-000006 |
| Q4 22 | 0002002654-23-000005 |
| Q3 22 | 0002002654-23-000004 |
| Q2 22 | 0002002654-23-000003 |
| Q1 22 | 0002002654-23-000002 |
| Q4 21 | 0002002654-23-000001 |
| Name | Title | CUSIP | Ticker | Value | Shares | Share Price | Investment | % of Portfolio |
|---|---|---|---|---|---|---|---|---|
| UNITED THERAPEUTICS CORP | Common | 91307C102 | $796,727,850 | 2,865,000 | SOLE | |||
| HORIZON THERAPEUTICS PLC | Common | G46188101 | $796,600,000 | 7,000,000 | SOLE | |||
| APELLIS PHARMACEUTICALS INC | Common | 03753U106 | $549,418,750 | 10,625,000 | SOLE | |||
| MADRIGAL PHARMACEUTICALS INC | Common | 558868105 | $481,815,000 | 1,660,000 | SOLE | |||
| ARGENX SE | Sponsored ADR | 04016X101 | $479,430,201 | 1,265,555 | SOLE | |||
| SAREPTA THERAPEUTICS INC | Common | 803607100 | $411,416,500 | 3,175,000 | SOLE | |||
| ASCENDIS PHARMA | Sponsored ADR | 04351P101 | $378,603,000 | 3,100,000 | SOLE | |||
| BIOMARIN PHARMACEUTICAL INC | Common | 09061G101 | $367,964,387 | 3,555,555 | SOLE | |||
| AMICUS THERAPEUTICS INC | Common | 03152W109 | $327,228,000 | 26,800,000 | SOLE | |||
| ALNYLAM PHARMACEUTICALS INC | Common | 02043Q107 | $262,603,250 | 1,105,000 | SOLE | |||
| MIRATI THERAPEUTICS INC | Common | 60468T105 | $251,722,197 | 5,555,555 | SOLE | |||
| SEAGEN INC | Common | 81181C104 | $242,241,350 | 1,885,000 | SOLE | |||
| XENON PHARMACEUTICALS INC | Common | 98420N105 | $193,207,000 | 4,900,000 | SOLE | |||
| IVERIC BIO INC | Common | 46583P102 | $144,517,500 | 6,750,000 | SOLE | |||
| KRYSTAL BIOTECH INC | Common | 501147102 | $111,700,200 | 1,410,000 | SOLE | |||
| BIOCRYST PHARMACEUTICALS INC | Common | 09058V103 | $103,894,000 | 9,050,000 | SOLE | |||
| KYMERA THERAPEUTICS INC | Common | 501575104 | $96,096,000 | 3,850,000 | SOLE | |||
| DICE THERAPEUTICS INC | Common | 23345J104 | $78,797,316 | 2,525,555 | SOLE | |||
| SYNDAX PHARMACEUTICALS INC | Common | 87164F105 | $67,442,500 | 2,650,000 | SOLE | |||
| CYMABAY THERAPEUTICS INC | Common | 23257D103 | $64,581,000 | 10,300,000 | SOLE | |||
| MANNKIND CORP | Common | 56400P706 | $47,957,000 | 9,100,000 | SOLE | |||
| NUVALENT INC | Common | 670703107 | $46,324,428 | 1,555,555 | SOLE | |||
| AVIDITY BIOSCIENCES INC | Common | 05370A108 | $45,489,500 | 2,050,000 | SOLE | |||
| IOVANCE BIOTHERAPEUTICS INC | Common | 462260100 | $44,857,800 | 7,020,000 | SOLE | |||
| MERSANA THERAPEUTICS INC | Common | 59045L106 | $44,243,000 | 7,550,000 | SOLE | |||
| KURA ONCOLOGY INC | Common | 50127T109 | $38,533,050 | 3,105,000 | SOLE | |||
| AADI BIOSCIENCES INC | Common | 00032Q104 | $36,557,828 | 2,849,402 | SOLE | |||
| ULTRAGENYX PHARMACEUTICAL INC | Common | 90400D108 | $34,747,500 | 750,000 | SOLE | |||
| MONTE ROSA THERAPEUTICS INC | Common | 61225M102 | $32,913,250 | 4,325,000 | SOLE | |||
| PMV PHARMACEUTICALS INC | Common | 69353Y103 | $26,622,000 | 3,060,000 | SOLE | |||
| DESIGN THERAPEUTICS INC | Common | 25056L103 | $23,312,998 | 2,272,222 | SOLE | |||
| AMYLYX PHARMACEUTICALS INC | Common | 03237H101 | $23,278,500 | 630,000 | SOLE | |||
| MARINUS PHARMACEUTICALS INC | Common | 56854Q200 | $12,537,000 | 3,150,000 | SOLE | |||
| TANGO THERAPEUTICS INC | Common | 87583X109 | $11,890,000 | 1,640,000 | SOLE | |||
| FENNEC PHARMACEUTICALS INC | Common | 31447P100 | $11,520,000 | 1,200,000 | SOLE | |||
| IO BIOTECH INC | Common | 449778109 | $4,728,531 | 2,055,883 | SOLE |